There are 8 approved therapies now available to the generalized myasthenia gravis (gMG) community. The Sumaira Foundation is pleased to share the first-of-its-kind, gMG Therapies Chart.
Our goal in laying out these new and available therapies side-by-side is to empower the patient community to discuss their treatment options with their doctors to make informed decisions about their best paths forward. At TSF, we’re strong advocates for shared decision-making between patients and their physicians, especially when it comes to deciding what long-term treatment(s) to opt for.
This chart has been created by TSF. Our Foundation works with therapy makers equally with an unbiased and objective lens.
DISCLAIMER: This chart is not intended to make direct comparisons between therapies. Data are extracted from separate clinical studies that differ in patient populations and study design. Cross-trial comparisons should be interpreted with caution in the absence of head-to-head studies.
Special thanks to Dr. Raffaele Iorio (subject-matter expert) and Tia Chakrapani for their efforts in bringing this chart to fruition.
Legend:
- Definition in text and audio format
Explore your treatment options by utilizing the filters below
 Uplizna® (inebilizumab-cdon) |  Imaavy® (nipocalimab-noli) |  Zilbrysq® (zilucoplan) |  Rystiggo® (rozanolixizumab-ulkh) |  Vyvgart® (efgartigimod alfa + hyaluronidase-qvfc) |  ULTOMIRIS® (ravulizumab-cwvz) |  Vyvgart® (efgartigimod alfa-fcab) |  Soliris® (eculizumab) | |
|---|---|---|---|---|---|---|---|---|
| Pharmacology aka How it Works | Anti-CD19 B cell depleting monoclonal antibody | FcRn blocker (monoclonal antibody) | Complement C5 inhibitor (macrocylic peptide) | FcRn blocker (monoclonal antibody) | FcRn blocker (Human IgG1 Fc fragment) | Complement C5 inhibitor (long-acting monoclonal antibody) | FcRn blocker (Human IgG1 Fc fragment) | Complement C5 inhibitor (monoclonal antibody) |
| Antibody Criteria | anti-AChR antibody positive (or Ab+) or anti-MuSK antibody positive (or Ab+) | anti-AChR antibody positive (or Ab+) or anti-MuSK antibody positive (or Ab+) | anti-AChR antibody positive (or Ab+) | anti-AChR antibody positive (or Ab+) or anti-MuSK antibody positive (or Ab+) | anti-AChR antibody positive (or Ab+), LRP4+, seronegative | anti-AChR antibody positive (or Ab+) | anti-AChR antibody positive (or Ab+), LRP4+, seronegative | anti-AChR antibody positive (or Ab+) |
| Drug Delivery Method | IV infusion (90 min) | IV infusion (initial ≥30 min; maintenance ≥15 min) | Subcutaneous self-injection (prefilled syringe) | Subcutaneous infusion (administered by HCP) | Subcutaneous injection (20-30 second injection via prefilled syringe; self-administered or by caregiver) | IV infusion (>= 30 min, weight based) | IV infusion (~1 hr) | IV infusion (35 min) |
| Administration Setting | Infusion center / outpatient clinic | Infusion center / outpatient clinic | Self-administered | Infusion center / outpatient clinic | Self-administered / caregiver-administered | Infusion center / outpatient clinic | Infusion center / outpatient clinic | Infusion center / outpatient clinic |
| Home Infusion | No Infusion | Home infusion offered by trained HCP | Infusion center only | Home infusion offered by trained HCP | No infusion | HCP-administered subcutaneous infusion | No infusion | Infusion center only |
| Frequency | Every 6 months, after 2 initial doses 2 weeks apart | Every 2 weeks (continuous), after initial loading dose | One daily (continuous) | Cycles of once weekly x 6 weeks; subsequent cycles based on clinical evaluation (>=63 days between cycle starts) | Cycles of 4 once-weekly administrations; initiation of subsequent cycles based on clinical evaluation (≥ 7 days from the end of the preceding cycle) | Every 8 weeks, starting 2 weeks after loading dose | Cycles of 4 once-weekly administrations; initiation of subsequent cycles based on clinical evaluation (≥ 7 days from the end of the preceding cycle) | Every 2 weeks, after 4 weekly induction doses + 5th dose at week 5 |
| Dosage | 300 mg IV per infusion | Loading: 30 mg/kg once; Maintenance: 15 mg/kg every 2 weeks | Weight-based: 56 kg: 16.6 mg; 56-77 kg: 23 mg; >77 kg: 32.4 mg daily | Weight-based: 50 kg: 420 mg; 50-100 kg: 560 mg; >=100 kg: 840 mg | 1008 mg per prefilled syringe | Loading: 2400-3000 mg (weight-based); Maintanence: 3000-3600 mg every 8 weeks | 10 mg/kg IV (max 1200 mg) per infusion | Induction: 900 mg weekly x 4 weeks; maintenance: 1200 mg every 2 weeks |
| Available for Pediatric Patients | No | 12 years and older | No | No | No | No | No | 6 years and older |
| Common Side Effects | Headache and infusion-related reaction | Infections, headache, peripheral edema, muscle spasms | Injection site reactions, upper respiratory, infection, diarrhea | Headache, diarrhea, pyrexia | Headache, respiratory tract infections | Headache, upper respiratory infection, diarrhea | Headache, respiratory tract infections, urinary tract infection | Headache, upper respiratory infection, nasopharyngitis |
| Potential Serious Side Effects | Infusion reactions, infections and low blood cell counts | Infections, headache, peripheral edema, muscle spasms | Menigococcal infections; pancreatitis (monitor lipase/ amylase) | Infections; reduced IgG levels; headache (severe) | Infections | Meningcoccal infections; infusion reactions | Infections | Meningococcal infections; infusion reactions |
| Manufacturer |  |  |  | |  |  | | |
| Year of FDA Approval | December 2025 | April 2025 | October 2023 | June 2023 | June 2023 | April 2022 | December 2021 | October 2017 |
| Assistance Programs | Amgen By Your Side | J&J withMe | UCB | UCB | Argenx | Alexion OneSourceTM | Argenx | Alexion OneSourceTM |
| Prescribing Information | Uplizna® (inebilizumab-cdon) Prescribing Information | Imaavy® (nipocalimab-noli) Prescribing Information
Health Canada PM | Zilbrysq (zilucoplan) Prescribing Information | Rystiggo® (rozanolixizumab-ulkh) Prescribing Information | Vyvgart Hytrulo® (efgartigimod alfa + hyaluronidase-qvfc) Prescribing Information | Ultomiris (ravulizumab-cwvz) Prescribing Information | VYVGART prescribing information | Argenx | Soliris (eculizumab) Prescribing Information |
No Matches
This patient education resource was made possible with support from argenx and Johnson & Johnson Innovative Medicine Canada